Catalog Sections:
|
 |
 |
|
|
| 18198. ANTEGREN: A BEACON OF HOPE HARVARD CASE STUDY 408025. This paper provides a Berkeley Research case study analysis and solution to a 2007 strategic management Harvard Business School case study (408025) by Joshua Margolis, Thomas DeLong and Terry Heymann on a biotechnology firm’s (Biogen Idec) development of the drug Antegren, promising in the treatment of Multiple Sclerosis and headed for FDA fast-track approval. The case analysis includes problem statement, analysis, assessment of alternatives, recommendations and implementation plan. TAGS: case study solution, biotechnology, pharmaceutical industry multiple sclerosis blockbuster drug strategic management crisis management, product recalls antegren disease management treatment case solution prescription drugs ethics. 10 pages, 7 footnotes, 5 bibliographic sources. RELATED PAPERS:MorphSys AG: The Evolution of a Biotechnology Business Model Harvard Case Solution |
|
$70
|
|
|
Copyright 2002 Academic Research Papers
Associate Term Paper Sites:
Academic Research Papers
Academic-Research-Papers
Research Central
Term Paper Assistance
|
